慢性髓性白血病:2025年关于诊断,治疗和监测的更新
Elias Jabbour1, Hagop Kantarjian1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
American journal of hematology
|August 2, 2024
概括
慢性髓性白血病 (CML) 是一种由费城染色体诊断的癌症. 治疗涉及氨酸激酶抑制剂 (TKIs),选择取决于治疗史和突变状态.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 慢性骨髓性白血病 (CML) 是一种骨髓增殖性新生体,每年约有10万人中就有2人受到影响.
- 在成人白血病诊断中,CML约占15%.
研究的目的:
- 审查慢性髓性白血病 (CML) 的诊断特征和治疗策略.
- 讨论氨酸激酶抑制剂 (TKI) 在CML前线和救援疗法的作用.
- 突出基因突变和患者因素对治疗选择的影响.
主要方法:
- 对CML的诊断标准的审查,重点是费城染色体 (BCR::ABL1融合基因).
- 对FDA批准的慢性阶段CML的一线TKI (imatinib,dasatinib,bosutinib,nilotinib) 的分析.
- 对TCI耐药性的二线TKI选择和管理策略的评估,包括T315I突变.
- 讨论异性干细胞移植和非TKI药物用于晚期或耐火性CML.
主要成果:
- 四种TKI被FDA批准用于前线CML-CP治疗,提供类似的生存益处.
- 第二代和第三代技术技能提供了更深入和更快的响应,但与第一代技术技能在前线环境中相比,它们没有改善整体生存率.
- 对于CML后失败,TKI的选择取决于患者的因素,疾病阶段和BCR::ABL1突变状态.
- 该T315I突变赋予了对大多数TKI的耐药性,需要特定的药物,如ponatinib或asciminib.
- 同源干细胞移植对于晚期CML或TKI耐药病例至关重要.
结论:
- 对CML-CP的前线TKI疗法已经发展,新的药物提供了快速反应.
- 对CML的治疗选择必须是个性化的,考虑疗效,耐药性突变和患者特异性因素.
- 救援疗法和干细胞移植对于管理进展或对初始治疗产生抗药性的CML至关重要.
更多相关视频
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
54
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Disorders of Leukocytes
924
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
924
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K